You are here
Home > Drugs > Pulmonary fibrosis (idopathic) -(IPF)

Feel free to use our complete database with charts, tables and examples.

 esbriet ® (pirfenidone) capsules 

Drug UPDATES:  ESBRIET ® (pirfenidone) capsules, for oral use
[Drug information  /  PDF]  
Dosing:  Click (+) next to Dosage and Administration section (drug info link)

Initial U.S. Approval:  2014

Mechanism of Action: The mechanism of action of pirfenidone in the treatment of IPF has not been established.

INDICATIONS AND USAGE:  ESBRIET is a pyridone indicated for the treatment of idiopathic pulmonary fibrosis (IPF).

HOW SUPPLIED: Capsules: 267 mg

 ofev ® (nintedanib) capsules 

Drug UPDATES:  OFEV ® (nintedanib) capsules, for oral use
[Drug information  /  PDF]  
Dosing:  Click (+) next to Dosage and Administration section (drug info link)

Initial U.S. Approval:  2014

Mechanism of Action: Nintedanib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (nRTKs). Nintedanib inhibits the following RTKs: platelet-derived growth factor receptor (PDGFR) a and ß, fibroblast growth factor receptor (FGFR) 1-3, vascular endothelial growth factor receptor (VEGFR) 1-3, and Fms-like tyrosine kinase-3 (FLT3). Among them, FGFR, PDGFR, and VEGFR have been implicated in IPF pathogenesis. Nintedanib binds competitively to the adenosine triphosphate (ATP) binding pocket of these receptors and blocks the intracellular signaling which is crucial for the proliferation, migration, and transformation of fibroblasts representing essential mechanisms of the IPF pathology. In addition, nintedanib inhibits the following nRTKs: Lck, Lyn and Src kinases. The contribution of FLT3 and nRTK inhibition to IPF efficacy is unknown.

INDICATIONS AND USAGE:  OFEV is a kinase inhibitor indicated for the treatment of idiopathic pulmonary fibrosis (IPF).

HOW SUPPLIED: Capsules: 150 mg and 100 mg

Reference(s)

National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates.  A local search option of this data can be found here.

Pulmonary fibrosis (idopathic) -(IPF)